College of Pharmacy, Chosun University, 309 Philmundaero, Dong-gu, Gwangju, 61452, Republic of Korea.
Arch Pharm Res. 2019 Feb;42(2):128-139. doi: 10.1007/s12272-019-01122-3. Epub 2019 Jan 25.
Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) induces conformational and functional changes to numerous key signaling molecules following proline-directed phosphorylation and its deregulation contributes to disease, particularly cancer. PIN1 is overexpressed in breast cancer, promoting cell proliferation and transformation in collaboration with several oncogenic signaling pathways, and is correlated with a poor clinical outcome. PIN1 level is also increased in certain gynecological cancers such as cervical, ovarian, and endometrial cancers. Although women with breast cancer are at risk of developing a second primary gynecological malignancy, particularly of the endometrium and ovary, the common oncogenic signaling pathway mediated by PIN1 has not been noted to date. This review discusses the roles of PIN1 in breast tumorigenesis and gynecological cancer progression, as well as the clinical effect of targeting this enzyme in breast and gynecological cancers.
肽基脯氨酰顺/反式异构酶 NIMA 相互作用 1（PIN1）在脯氨酸定向磷酸化后诱导许多关键信号分子的构象和功能变化，其失调会导致疾病，特别是癌症。PIN1 在乳腺癌中过度表达，与几种致癌信号通路协同促进细胞增殖和转化，并且与不良的临床结局相关。PIN1 水平在某些妇科癌症中也会升高，如宫颈癌、卵巢癌和子宫内膜癌。尽管患有乳腺癌的女性有发展第二原发妇科恶性肿瘤的风险，特别是子宫内膜癌和卵巢癌，但迄今为止尚未注意到由 PIN1 介导的常见致癌信号通路。本文讨论了 PIN1 在乳腺癌发生和妇科癌症进展中的作用，以及针对这种酶在乳腺癌和妇科癌症中的临床效果。
